Skip to main content

Table 1 Clinical characteristics and blood lipid level in non-progressive and progressive lung cancer patients with cisplatin treatment

From: SIAH1 ubiquitination-modified HMGCR inhibits lung cancer progression and promotes drug sensitivity through cholesterol synthesis

 

Non-progression (n = 15)

Progression (n = 27)

P

Age (years)

53.94 ± 6.15

55.48 ± 7.47

0.503

Smoking rate (%)

60 (%)

52 (%)

0.647

BMI (kg/m 2 )

22.43 ± 2.51

22.23 ± 2.19

0.788

TG (mmol/L)

1.16 ± 0.36

1.24 ± 0.29

0.398

TC (mmol/L)

4.21 ± 0.54

5.02 ± 0.83

0.002 *

HDL (mmol/L)

1.29 ± 0.27

1.36 ± 0.26

0.476

LDL (mmol/L)

2.41 ± 0.54

2.33 ± 0.62

0.706

  1. BMI body mass index, TC Total cholesterol, TG Total triglyceride, HDL High-density lipoprotein cholesterol, LDL Low-density lipoprotein cholesterol. Non-progression group: there is no progress after a period of treatment of cisplatin, progression group: there is medical progress after a period of treatment of cisplatin